Navigation Links
Sirtris' review of sirtuin therapeutics for diseases of aging in Nature Reviews Drug Discovery
Date:10/1/2008

CAMBRIDGE, MA [October 1, 2008] Sirtris, a GSK company focused on discovering and developing small molecule drugs to treat diseases of aging such as Type 2 Diabetes, announced today that it published a new review article on the growing body of sirtuin research and its potential to treat diseases of aging such as Type 2 Diabetes, mitochondrial disorders, inflammation, cancer, and heart disease. Entitled "SIRTUINS Novel Therapeutic Targets to Treat Age-Associated Diseases," the review appears in today's issue of the journal Nature Reviews Drug Discovery.

Sirtuins are a family of enzymes which target genes that control aging. There are a total of seven sirtuin enzymes that exist in mammals. SIRT1 is the founding member of this class of enzymes and is currently the most studied of the group. When activated, SIRT1 appears to mimic some of the positive health effects seen in calorie-restricted animals.

"We are excited to be at the forefront of this research, which continues to intensify as we see positive results from early human clinical studies," said Christoph Westphal, M.D., Ph.D., Chief Executive Officer of Sirtris, a GSK company. "The body of clinical data supporting the role of SIRT1 activation as a viable mechanism for treating a broad range of diseases of metabolism and aging is growing."

Peter Elliott, Ph.D., Senior Vice President of Development, said, "At Sirtris, we are targeting the genes which control the aging process with the potential to treat diseases of aging such as diabetes, neurodegeneration, cancer, and inflammation."

This review highlights the molecular mechanism of action of sirtuins with a view towards diseases where SIRT1 activation shows therapeutic promise. Such diseases of aging include Type 2 Diabetes and mitochondrial disorders, cardiovascular disease, cancer, neurodegeneration and inflammatory diseases. One of the first small molecules discovered to exhibit the positive effects of calorie restriction is resveratrol, a natural ingredient found in red wine. Since then, Sirtris has developed its own proprietary formulation of resveratrol, SRT501. Early clinical studies in patients with Type 2 Diabetes indicate that SRT501 may lower glucose and improve insulin sensitivity. Sirtris also has new chemical entities (NCEs) which are structurally unrelated to and one-thousand times more potent than resveratrol. Sirtris' first new chemical entity is currently being evaluated for safety and tolerability in a Phase 1a study in humans.

"We are beginning to understand more about activation of other enzymes in the sirtuin family, SIRT2-7, and we're encouraged by early data that indicates a role for other sirtuins in multiple therapeutic areas," continued Dr. Westphal.


'/>"/>

Contact: Caton Lovett
caton@purecommunicationsinc.com
910-509-3975
Pure Communications Inc.
Source:Eurekalert

Related biology news :

1. Sirtris unveils promising, novel SIRT1 activators for treating diseases of aging
2. Review article provides tools for the Rosaceae genomics community
3. Medicines derived from cannabis: a review of adverse events
4. Stanford researchers publish review of US medical device regulation
5. Media invitation: 20th EORTC-NCI-ACR Symposium on Molecular Targets and Cancer Therapeutics
6. CU-Boulder, biotech firm team up on python project in search for human cardiac therapeutics
7. Michael J. Fox Foundation PD Therapeutics Conference
8. Galapagos and Cystic Fibrosis Foundation Therapeutics announce drug discovery collaboration
9. Iron-moving malfunction may underlie neurodegenerative diseases, aging
10. Gaining a better understanding of kidney diseases
11. Biodegradable polymers show promise for improving treatment of acute inflammatory diseases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/20/2017)... 20, 2017 At this year,s CeBIT Chancellor Dr. ... manufacturer DERMALOG. The Chancellor came to the DERMALOG stand together with the ... year,s CeBIT partner country. At the largest German biometrics company the two ... face and iris recognition as well as DERMALOGĀ“s multi-biometrics system.   ... ...
(Date:3/13/2017)... , March 13, 2017 Future of security: Biometric ... ... DERMALOGs Face Matching enables to match face pictures ... the basis to identify individuals. (PRNewsFoto/Dermalog Identification Systems) ... DERMALOG,s "Face Matching" is the fastest software for biometric Face ...
(Date:3/7/2017)... Brandwatch , the leading social intelligence company, today announces that ... uncover insights to support its reporting, help direct future campaigns, and ... youth charity will be using Brandwatch Analytics social listening and analytics ... of the topics and issues that are a priority for its ... "Until recently ...
Breaking Biology News(10 mins):
(Date:3/23/2017)... 2017 NetworkNewsWire Editorial Coverage  ... Cancer remains one ... on health care systems, in terms of costs and resources. ... does the development of innovative and efficient therapies that demonstrate ... many types of cancer treatments, a growing number of patients ...
(Date:3/22/2017)... TARRYTOWN, N.Y. , March 22, 2017 Regeneron ... among the Regeneron Genetics Center (RGC), U.K. Biobank and GSK ... in the U.K. Biobank resource. The initiative will enable researchers ... of new medicines for a wide range of serious and ... ...
(Date:3/22/2017)... , March 22, 2017 Oramed Pharmaceuticals ... www.oramed.com ), a clinical-stage ... drug delivery systems, announced today that Dr. ... deliver a presentation titled, "Oral Insulin for Diabetes ... Cambridge Healthtech Institute,s Oligonucleotide and Peptide Therapeutics (OPT) Boston Conference ...
(Date:3/22/2017)... --  Boston Biomedical , an industry leader in the ... stemness pathways, today announced its Board of Directors has ... Officer, effective April 24, 2017. Ms. ... FACP, who has led Boston Biomedical since he founded ... Biomedical has grown from a "garage startup" without technology ...
Breaking Biology Technology: